{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2+x+500+mg+Metformin+%28Glumetza%29&page=2",
    "query": {
      "intervention": "2 x 500 mg Metformin (Glumetza)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2+x+500+mg+Metformin+%28Glumetza%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2+x+500+mg+Metformin+%28Glumetza%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T02:08:35.811Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01042379",
      "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Breast Tumors",
        "Angiosarcoma",
        "TNBC - Triple-Negative Breast Cancer",
        "HER2-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "Hormone Receptor Negative Tumor",
        "Early-stage Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Standard Therapy",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 479 (Ganitumab) plus Metformin",
          "type": "DRUG"
        },
        {
          "name": "MK-2206 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "T-DM1 and Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Ganetespib",
          "type": "DRUG"
        },
        {
          "name": "ABT-888",
          "type": "DRUG"
        },
        {
          "name": "Neratinib",
          "type": "DRUG"
        },
        {
          "name": "PLX3397",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 4 cycle",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib plus Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Patritumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 8 cycle",
          "type": "DRUG"
        },
        {
          "name": "SGN-LIV1A",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab plus Olaparib",
          "type": "DRUG"
        },
        {
          "name": "SD-101 + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib plus trastuzumab and pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab plus REGN3767",
          "type": "DRUG"
        },
        {
          "name": "Trilaciclib with or without trastuzumab + pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "SYD985 ([vic-]trastuzumab duocarmazine)",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARX788",
          "type": "DRUG"
        },
        {
          "name": "ARX788 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "VV1 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan + Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Zanidatamab",
          "type": "DRUG"
        },
        {
          "name": "Lasofoxifene",
          "type": "DRUG"
        },
        {
          "name": "Z-endoxifen",
          "type": "DRUG"
        },
        {
          "name": "ARV-471",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Endoxifen + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig + TDXd",
          "type": "DRUG"
        },
        {
          "name": "Dan222 + Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab + Cemiplimab + Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584 + Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Ivonescimab (20mg/kg Q3W)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2010-03-01",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01042379"
    },
    {
      "nct_id": "NCT02065752",
      "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Canagliflozin, 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR, 500 mg",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 1, 50 mg/500 mg",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 2, 50 mg/500 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 2,
      "start_date": "2014-02",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-06-17",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065752"
    },
    {
      "nct_id": "NCT02071368",
      "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR, 500 mg",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 1, 150 mg/500",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 2, 150 mg/500 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 3,
      "start_date": "2014-02",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-07-01",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02071368"
    },
    {
      "nct_id": "NCT06042855",
      "title": "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Susanna Naggie, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 3214,
      "start_date": "2023-09-05",
      "completion_date": "2024-11-04",
      "has_results": true,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 110,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06042855"
    },
    {
      "nct_id": "NCT00283816",
      "title": "Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Oral Contraceptive Pill",
          "type": "DRUG"
        },
        {
          "name": "Lifestyle Management Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Quality of Life Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Oral Glucose Tolerance Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood work",
          "type": "PROCEDURE"
        },
        {
          "name": "Abdominal Ultra Sound",
          "type": "PROCEDURE"
        },
        {
          "name": "Dual-energy x-ray absorptiometry (DEXA scan)",
          "type": "PROCEDURE"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 18 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2006-01",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2015-05-15",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00283816"
    },
    {
      "nct_id": "NCT01551615",
      "title": "A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Metformin 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "Vandetanib 800 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 14,
      "start_date": "2012-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2016-08-29",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01551615"
    },
    {
      "nct_id": "NCT01845077",
      "title": "Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "2x500 mg Metformin (Glumetza)",
          "type": "DRUG"
        },
        {
          "name": "5 mg Linagliptin/1000 mg Metformin FDC",
          "type": "DRUG"
        },
        {
          "name": "5 mg Linagliptin (Tradjenta)",
          "type": "DRUG"
        },
        {
          "name": "3x500 mg Metformin (Glumetza)",
          "type": "DRUG"
        },
        {
          "name": "2 x 500 mg Metformin (Glumetza)",
          "type": "DRUG"
        },
        {
          "name": "5 mg Linagliptin/1000mg Metformin FDC",
          "type": "DRUG"
        },
        {
          "name": "2 x 2.5 mg Linagliptin/750 mg Metformin FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 72,
      "start_date": "2013-05",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2014-08-19",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01845077"
    },
    {
      "nct_id": "NCT01002807",
      "title": "Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "Glucophage",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 15,
      "start_date": "2009-11",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2016-10-17",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01002807"
    },
    {
      "nct_id": "NCT07372625",
      "title": "A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "TP53 Y220C Mutation",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "metformin hydrochloride 500 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "rosuvastatin 10 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "repaglinide 0.5 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "midazolam hydrochloride syrup",
          "type": "DRUG"
        },
        {
          "name": "rezatapopt",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PMV Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2026-02-04",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07372625"
    },
    {
      "nct_id": "NCT01638676",
      "title": "A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2012-07",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-10-11T02:08:35.811Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01638676"
    }
  ]
}